180 related articles for article (PubMed ID: 10466436)
21. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
[TBL] [Abstract][Full Text] [Related]
22. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
23. New treatment strategies for hormone refractory prostate cancer.
Redman BG; Pienta KJ
Semin Urol; 1995 May; 13(2):164-9. PubMed ID: 7638474
[No Abstract] [Full Text] [Related]
24. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
25. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
[TBL] [Abstract][Full Text] [Related]
26. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
27. UK studies on suramin therapy in hormone resistant prostate cancer.
Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
[TBL] [Abstract][Full Text] [Related]
28. Treatment of hormone refractory prostate cancer.
Knox JJ; Moore MJ
Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
[TBL] [Abstract][Full Text] [Related]
30. The treatment of hormone refractory prostate cancer.
Panvichian R; Pienta KJ
Compr Ther; 1996 Feb; 22(2):81-7. PubMed ID: 8689867
[No Abstract] [Full Text] [Related]
31. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
32. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
[TBL] [Abstract][Full Text] [Related]
33. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
[TBL] [Abstract][Full Text] [Related]
34. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
35. Suramin is synergistic with vinblastine in human colonic tumor cell lines: effect of cell density and timing of drug delivery.
Frommel TO
Anticancer Res; 1997; 17(3C):2065-71. PubMed ID: 9216665
[TBL] [Abstract][Full Text] [Related]
36. Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
El-Rayes BF; Grignon R; Aslam N; Aranha O; Sarkar FH
Int J Oncol; 2002 Jul; 21(1):207-11. PubMed ID: 12063570
[TBL] [Abstract][Full Text] [Related]
37. Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer.
Atkins CD
J Clin Oncol; 1995 Mar; 13(3):797. PubMed ID: 7884440
[No Abstract] [Full Text] [Related]
38. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Speicher LA; Barone L; Tew KD
Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
[TBL] [Abstract][Full Text] [Related]
39. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.
Attivissimo LA; Fetten JV; Kreis W
Am J Clin Oncol; 1996 Dec; 19(6):581-3. PubMed ID: 8931676
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Naik H; Lehr JE; Pienta KJ
Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]